NPI: 1194790055 · STUART, FL 34994 · Specialist · NPI assigned 02/22/2006
Authorized official LARAWAY, DENNIS controls 20+ related entities in our dataset. Read more
| Authorized Official | LARAWAY, DENNIS (EXECUTIVE VP CHIEF FINANCE OFFICER) |
| NPI Enumeration Date | 02/22/2006 |
Other providers sharing the same authorized official: LARAWAY, DENNIS
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 107,495 | $1.80M |
| 2019 | 234,009 | $5.34M |
| 2020 | 197,942 | $3.28M |
| 2021 | 254,709 | $5.09M |
| 2022 | 244,855 | $6.26M |
| 2023 | 78,325 | $3.24M |
| 2024 | 23,676 | $1.03M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 48,754 | 42,622 | $4.50M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 36,184 | 32,514 | $2.50M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 26,410 | 8,339 | $2.33M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 26,714 | 7,829 | $2.10M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30,423 | 24,339 | $2.05M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 25,380 | 7,353 | $1.88M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6,301 | 5,488 | $858K |
| 70450 | Computed tomography, head or brain; without contrast material | 7,607 | 6,247 | $796K |
| 96361 | Intravenous infusion, hydration; each additional hour | 15,420 | 11,462 | $721K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,785 | 2,383 | $382K |
| J7030 | Infusion, normal saline solution , 1000 cc | 30,563 | 20,566 | $333K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4,407 | 4,075 | $306K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5,969 | 4,516 | $229K |
| G0378 | Hospital observation service, per hour | 12,234 | 5,175 | $197K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 6,855 | 5,596 | $190K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 5,342 | 4,624 | $189K |
| 80048 | Basic metabolic panel (calcium, ionized) | 34,697 | 25,950 | $188K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1,429 | 1,260 | $183K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 10,208 | 8,655 | $178K |
| 80053 | Comprehensive metabolic panel | 28,785 | 23,294 | $171K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7,398 | 5,433 | $171K |
| 97162 | 2,316 | 2,025 | $160K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 2,046 | 1,561 | $152K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 4,567 | 3,599 | $146K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 5,718 | 5,449 | $139K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 4,647 | 3,847 | $129K |
| J1170 | Injection, hydromorphone, up to 4 mg | 4,865 | 3,159 | $120K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 6,353 | 5,857 | $113K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 3,580 | 3,254 | $108K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 5,894 | 1,724 | $108K |
| 59025 | Fetal non-stress test | 1,339 | 967 | $105K |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 7,125 | 2,205 | $96K |
| 36415 | Collection of venous blood by venipuncture | 26,113 | 18,908 | $95K |
| 71046 | Radiologic examination, chest; 2 views | 11,093 | 10,146 | $92K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 6,802 | 6,177 | $88K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 3,706 | 2,907 | $84K |
| 87088 | 16,885 | 13,731 | $82K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 1,593 | 1,370 | $81K |
| J0690 | Injection, cefazolin sodium, 500 mg | 2,419 | 1,611 | $80K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1,603 | 1,354 | $79K |
| 87486 | 2,048 | 1,898 | $79K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4,143 | 3,565 | $78K |
| 97161 | 1,722 | 1,434 | $76K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 5,444 | 3,851 | $71K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2,987 | 2,005 | $71K |
| 97166 | 765 | 687 | $67K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1,963 | 993 | $65K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 417 | 376 | $65K |
| J7050 | Infusion, normal saline solution, 250 cc | 5,389 | 3,233 | $65K |
| 97014 | 396 | 124 | $63K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 3,402 | 2,521 | $59K |
| J7510 | Prednisolone oral, per 5 mg | 1,086 | 1,027 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 57,316 | 43,553 | $54K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 2,824 | 2,269 | $48K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 796 | 722 | $47K |
| 92523 | 568 | 537 | $47K | |
| 71045 | Radiologic examination, chest; single view | 16,831 | 14,412 | $46K |
| 87070 | 4,158 | 3,415 | $45K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 2,170 | 1,815 | $45K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6,202 | 2,894 | $45K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 718 | 671 | $45K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 2,627 | 2,137 | $42K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7,024 | 5,002 | $41K |
| 81025 | 16,432 | 14,413 | $40K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 1,822 | 1,326 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 19,304 | 15,465 | $38K |
| 99232 | Subsequent hospital care, per day, moderate complexity | 2,529 | 455 | $38K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1,598 | 1,415 | $37K |
| 73610 | 1,704 | 1,554 | $36K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 1,447 | 1,150 | $35K |
| 76830 | Ultrasound, transvaginal | 924 | 840 | $35K |
| 73630 | 2,378 | 2,096 | $34K | |
| 81003 | 13,397 | 11,637 | $34K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1,159 | 1,075 | $34K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6,441 | 6,147 | $33K |
| 76801 | 1,846 | 1,567 | $33K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 19,645 | 16,060 | $33K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 10,003 | 7,307 | $31K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 3,931 | 3,154 | $29K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 583 | 532 | $29K |
| 97116 | 2,351 | 1,107 | $29K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 814 | 740 | $28K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 5,505 | 3,653 | $28K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 469 | 450 | $28K |
| 73564 | 2,177 | 1,852 | $28K | |
| 81001 | 26,773 | 22,246 | $28K | |
| 84484 | 16,487 | 9,545 | $27K | |
| J2704 | Injection, propofol, 10 mg | 4,198 | 3,357 | $26K |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | 633 | 280 | $26K |
| 76775 | 578 | 509 | $26K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 579 | 478 | $26K |
| 82948 | 2,163 | 1,097 | $26K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2,010 | 1,365 | $25K |
| J1644 | Injection, heparin sodium, per 1000 units | 3,328 | 1,331 | $25K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5,750 | 2,980 | $25K |
| 85610 | 13,848 | 9,976 | $25K | |
| 90714 | 963 | 845 | $24K | |
| 73130 | 1,772 | 1,576 | $24K | |
| 73110 | 1,251 | 1,126 | $24K | |
| J2060 | Injection, lorazepam, 2 mg | 1,639 | 1,202 | $24K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1,441 | 1,170 | $22K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1,128 | 959 | $22K |
| 71250 | 701 | 572 | $22K | |
| 73030 | 1,571 | 1,343 | $21K | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 711 | 319 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 347 | 163 | $21K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 1,865 | 1,600 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 318 | 279 | $21K |
| 85027 | 9,351 | 6,434 | $21K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 14,072 | 10,757 | $20K |
| 76641 | 353 | 276 | $20K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 378 | 316 | $18K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 961 | 573 | $18K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,027 | 909 | $18K |
| 82550 | 9,915 | 7,807 | $18K | |
| 72110 | 1,833 | 1,607 | $17K | |
| 85730 | 9,335 | 7,430 | $17K | |
| 74018 | 928 | 860 | $16K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 12,424 | 9,765 | $16K |
| J1650 | Injection, enoxaparin sodium, 10 mg | 2,403 | 1,398 | $15K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 584 | 495 | $15K |
| 87040 | 8,175 | 4,354 | $14K | |
| 86850 | 1,906 | 1,542 | $14K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 241 | 233 | $14K |
| 82962 | 6,376 | 2,757 | $14K | |
| 82553 | 7,372 | 5,860 | $14K | |
| J8540 | Dexamethasone, oral, 0.25 mg | 993 | 930 | $14K |
| 73080 | 726 | 659 | $14K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 600 | 504 | $13K |
| 74019 | 1,963 | 1,759 | $13K | |
| 93971 | 854 | 726 | $13K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 8,644 | 5,591 | $12K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 256 | 166 | $12K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 276 | 225 | $12K |
| 80076 | 13,638 | 11,541 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | 7,442 | 6,069 | $11K |
| 76536 | 199 | 181 | $11K | |
| 84702 | 3,334 | 2,598 | $11K | |
| 80061 | Lipid panel | 8,626 | 6,988 | $11K |
| 87210 | 2,104 | 1,919 | $10K | |
| J3360 | Injection, diazepam, up to 5 mg | 394 | 331 | $10K |
| 12011 | 445 | 407 | $10K | |
| 97165 | 443 | 356 | $10K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 1,262 | 562 | $10K |
| 83735 | 6,632 | 4,941 | $9K | |
| J1815 | Injection, insulin, per 5 units | 1,695 | 742 | $9K |
| 83690 | 14,645 | 12,317 | $9K | |
| 73502 | 905 | 760 | $9K | |
| 96376 | 3,076 | 2,081 | $9K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 671 | 606 | $8K |
| 92567 | 235 | 229 | $8K | |
| 83605 | 12,251 | 9,366 | $8K | |
| 12001 | 422 | 382 | $8K | |
| 87186 | 6,469 | 4,560 | $8K | |
| 72131 | 211 | 170 | $8K | |
| C1769 | Guide wire | 1,269 | 960 | $8K |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 902 | 701 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,645 | 1,724 | $7K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 4,894 | 2,691 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 77 | 73 | $7K |
| J1756 | Injection, iron sucrose, 1 mg | 644 | 323 | $7K |
| 99152 | 1,086 | 844 | $7K | |
| 87205 | 2,938 | 2,205 | $7K | |
| 83880 | 3,165 | 2,506 | $7K | |
| 97535 | Self-care/home management training, each 15 minutes | 935 | 517 | $7K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2,048 | 1,898 | $7K |
| 72050 | 703 | 624 | $6K | |
| 85379 | 3,504 | 3,099 | $6K | |
| 29130 | 60 | 40 | $6K | |
| 99205 | Prolong outpt/office vis | 77 | 67 | $5K |
| 70491 | 45 | 40 | $5K | |
| 86140 | 4,847 | 4,123 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2,309 | 1,884 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1,210 | 1,022 | $5K |
| 77072 | 120 | 117 | $5K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 69 | 61 | $5K |
| J2550 | Injection, promethazine hcl, up to 50 mg | 127 | 106 | $5K |
| 92587 | 294 | 281 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2,245 | 2,051 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | 4,278 | 3,440 | $4K |
| 99233 | Prolong inpt eval add15 m | 177 | 110 | $4K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 799 | 597 | $4K |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | 1,962 | 727 | $4K |
| 84100 | 3,461 | 2,471 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 581 | 446 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2,243 | 2,051 | $4K |
| 82140 | 1,253 | 1,000 | $4K | |
| 87634 | 1,328 | 1,275 | $3K | |
| 76818 | 39 | 25 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 89 | 78 | $3K |
| 73590 | 330 | 299 | $3K | |
| 82150 | 6,856 | 5,862 | $3K | |
| 94664 | 2,753 | 2,418 | $3K | |
| 86900 | 2,971 | 2,417 | $3K | |
| 98966 | 110 | 43 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 118 | 101 | $3K |
| 84439 | 2,352 | 1,957 | $3K | |
| 98967 | 64 | 41 | $3K | |
| 87507 | 211 | 190 | $3K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 71 | 63 | $3K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 216 | 178 | $3K |
| 73090 | 223 | 203 | $3K | |
| 99153 | Mod sedat endo service >5yrs | 263 | 202 | $3K |
| 92557 | 23 | 23 | $3K | |
| 29125 | 463 | 424 | $3K | |
| 93970 | 70 | 60 | $3K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 3,580 | 2,045 | $2K |
| 87581 | 2,049 | 1,899 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2,056 | 1,903 | $2K |
| 82607 | 1,916 | 1,538 | $2K | |
| 70486 | 80 | 66 | $2K | |
| 80069 | 643 | 355 | $2K | |
| 86901 | 2,971 | 2,417 | $2K | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 150 | 64 | $2K |
| 82270 | 254 | 218 | $2K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 169 | 114 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,465 | 1,331 | $2K |
| 97163 | 13 | 13 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 40 | 12 | $2K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 87 | 60 | $2K |
| 85652 | 3,033 | 2,576 | $2K | |
| 84112 | 12 | 12 | $2K | |
| 36430 | 42 | 26 | $2K | |
| 82570 | 2,121 | 1,649 | $2K | |
| 86308 | 193 | 185 | $2K | |
| 84703 | 3,526 | 3,186 | $2K | |
| 71101 | 163 | 148 | $2K | |
| 99215 | Prolong outpt/office vis | 70 | 60 | $2K |
| 82247 | 315 | 209 | $1K | |
| A6248 | Hydrogel dressing, wound filler, gel, per fluid ounce | 881 | 349 | $1K |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 102 | 85 | $1K |
| A6219 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 429 | 266 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 439 | 305 | $1K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 509 | 427 | $1K |
| 72100 | 198 | 174 | $1K | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 100 | 83 | $1K |
| 99222 | Initial hospital care, per day, moderate complexity | 58 | 36 | $1K |
| 76870 | 33 | 28 | $1K | |
| 83540 | 913 | 724 | $1K | |
| 72141 | 26 | 25 | $1K | |
| 10060 | 49 | 42 | $965.99 | |
| 91300 | 128 | 123 | $913.94 | |
| 51701 | 892 | 740 | $895.99 | |
| J1940 | Injection, furosemide, up to 20 mg | 43 | 25 | $872.37 |
| 76813 | 37 | 36 | $866.16 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 22 | 16 | $791.77 |
| 82728 | 728 | 594 | $762.62 | |
| 72170 | 71 | 49 | $588.65 | |
| 87807 | 913 | 839 | $520.26 | |
| 73140 | 28 | 26 | $510.36 | |
| 84481 | 737 | 602 | $507.66 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 125 | 114 | $473.55 |
| 93880 | 27 | 25 | $473.36 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 48 | 40 | $434.14 |
| C1729 | Catheter, drainage | 114 | 76 | $412.77 |
| 92579 | 20 | 20 | $403.68 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 88 | 65 | $390.00 |
| 96367 | 199 | 94 | $389.20 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5,089 | 3,170 | $377.80 |
| 82805 | 16 | 14 | $355.57 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 147 | 51 | $335.50 |
| 12002 | 25 | 24 | $327.86 | |
| 82043 | 896 | 705 | $320.05 | |
| A6217 | Gauze, non-impregnated, non-sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 241 | 126 | $255.45 |
| 85046 | 164 | 97 | $249.56 | |
| 51798 | 79 | 64 | $239.29 | |
| 84145 | 661 | 524 | $224.57 | |
| A6252 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 477 | 207 | $215.12 |
| 72072 | 34 | 25 | $214.50 | |
| 86923 | 165 | 76 | $209.26 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 96 | 82 | $181.43 |
| 82248 | 575 | 405 | $180.16 | |
| 84550 | 717 | 563 | $177.39 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 30 | 24 | $173.89 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 50 | 42 | $167.06 |
| 0001A | 377 | 222 | $157.54 | |
| 76937 | 174 | 135 | $150.00 | |
| 88300 | 51 | 36 | $146.01 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 14 | 12 | $127.21 |
| 84156 | 807 | 605 | $122.28 | |
| 0002A | 406 | 238 | $114.58 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 43 | 36 | $109.98 |
| 82010 | 140 | 121 | $106.91 | |
| 82746 | 205 | 148 | $100.50 | |
| 80164 | 76 | 53 | $99.24 | |
| 70360 | 12 | 12 | $97.74 | |
| 73552 | 31 | 25 | $55.16 | |
| 1160F | 2,116 | 1,873 | $48.57 | |
| 80074 | 30 | 27 | $37.10 | |
| 94760 | 484 | 326 | $33.42 | |
| 83970 | 46 | 39 | $29.25 | |
| 83615 | 212 | 148 | $26.24 | |
| 83550 | 384 | 311 | $20.02 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 38 | 37 | $18.54 |
| 88304 | 221 | 179 | $13.15 | |
| 80047 | 18 | 18 | $11.91 | |
| 3078F | 930 | 794 | $0.00 | |
| 1159F | 2,116 | 1,874 | $0.00 | |
| 0353U | 108 | 104 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 79 | 66 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 88 | 67 | $0.00 |
| 85014 | 19 | 12 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 30 | 24 | $0.00 |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 27 | 12 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 76 | 51 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 27 | 25 | $0.00 |
| 3077F | 15 | 13 | $0.00 | |
| 29515 | 30 | 29 | $0.00 | |
| 1125F | 833 | 732 | $0.00 | |
| 3079F | 105 | 92 | $0.00 | |
| 3074F | 1,246 | 1,078 | $0.00 | |
| 85018 | 20 | 13 | $0.00 | |
| 80177 | 15 | 13 | $0.00 | |
| J3490 | Unclassified drugs | 300 | 174 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 14 | 13 | $0.00 |
| 73060 | 14 | 12 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 29 | 28 | $0.00 |
| 88307 | 19 | 12 | $0.00 | |
| 86780 | 19 | 12 | $0.00 |